Human papillomavirus type 16 E6 and E7 proteins (HPV16 E6/E7)

The **Human papillomavirus type 16 E6 and E7 proteins** are viral oncoproteins expressed by the high-risk HPV16 genotype, the most common cause of HPV-driven cancers such as cervical cancer. These proteins are central to the oncogenic process: E6 promotes the degradation of the tumor suppressor p53, thereby inhibiting apoptosis and DNA damage responses, while E7 disrupts cell cycle regulation by binding and degrading the retinoblastoma protein (pRb), releasing E2F transcription factors to drive unscheduled cell cycle progression[2][5][6][1][4]. Both proteins interact with numerous host factors and override critical cellular checkpoints, facilitating malignant transformation. These oncoproteins are the molecular basis for diagnostic assays and are prime targets for therapeutic vaccine and immunotherapy strategies[5][6][3]. Detection of E6/E7 expression serves as a highly specific biomarker for high-risk HPV-associated malignancies, whereas immune strategies targeting E6/E7 aim to harness or boost T-cell responses for cancer therapy. Their persistent expression and essential functions in HPV-driven tumors make them robust and widely accepted therapeutic targets, yet direct, clinically approved small molecule inhibitors are still lacking; instead, approaches have focused on immune targeting and gene editing/silencing[5][2][6].

Other names

HPV-16 E6 oncoproteinHPV-16 E7 oncoproteinHPV16 E6HPV16 E7

Vaccine-induced cytotoxic T lymphocyte (CTL) response against E6/E7-expressing cells (cancer immunotherapy) - Peptide/protein-based immunotherapeutics designed to trigger tumor cell destruction by immune targeting of E6/E7 antigens - Experimental gene silencing (via siRNA, CRISPR, or antisense) to reduce E6/E7 expression